Equity research analysts tracking Hester Biosciences maintain a generally constructive outlook, with consensus recommendations leaning toward a Buy or Hold stance depending on domestic formulation performance and veterinary vaccine demand. Analysts emphasize that export market expansions, government tender execution, and scaling animal healthcare segments serve as primary catalysts supporting intermediate price targets.